Beckman Coulter DxC 500i Clinical Analyzer Modules using software version 1.5 or lower: 1) DxC...
FDA Device Recall #Z-2973-2026 - Class II, July 15, 2026
Recall Summary
| Recall Number | Z-2973-2026 |
| Classification | Class II - Moderate risk |
| Date Initiated | July 15, 2026 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Beckman Coulter Inc. |
| Location | Brea, CA |
| Product Type | Devices |
Product Description
Beckman Coulter DxC 500i Clinical Analyzer Modules using software version 1.5 or lower: 1) DxC 500 AU Module w/ISE, DxC 500i, Part Number C63522; 2) DxC 500 AU Module, DxC 500i, Part Number C63521; 3) Access 2 Module, DxC 500i, Part Number C13252; DxC 500 AU Clinical Chemistry Analyzers
Reason for Recall
a software defect in which the Parameter Package (PP) import logic overwrites all predefined calculated test rules, including those previously modified by the user, upon import of a new Parameter Package version. As a result, usercustomized calculated test rules revert silently to their default expressions, potentially generating erroneous patient test results without an explicit error notification. The issue affects instruments running software version 1.5 or lower and only occurs when a new Parameter Package is imported to a system that already has an existing Parameter Package onboard; new installations are not affected.
Distribution Pattern
Worldwide distribution - US Nationwide.
Lot / Code Information
1) Part Number C63522, UDI/DI 14987666545089; 2) Part Number C63521, UDI/DI 14987666545072; 3) Part Number C13252, UDI/DI 15099590742331.
Other Recalls from Beckman Coulter Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-2974-2026 | Class II | Beckman Coulter DxC 500 AU Clinical Analyzer Mo... | Jul 15, 2026 |
| Z-2888-2026 | Class II | REF # D23352, MicroScan LabPro V5.03 Panel Upda... | Jun 26, 2026 |
| Z-2889-2026 | Class II | REF # D23354, MicroScan LabPro V5.03 Panel Upda... | Jun 26, 2026 |
| Z-0541-2026 | Class II | DxFLEX Flow Cytometer Catalog Number C78500 UD... | Sep 22, 2025 |
| Z-0441-2026 | Class II | SYNCHRON Systems Direct LDL Cholesterol (LDLD) ... | Sep 17, 2025 |
Frequently Asked Questions
A software recall means the device's embedded software or firmware has a defect that could affect its performance or safety. Many software recalls are corrected through firmware updates that can be applied without physically replacing the device. For implantable devices, the update may be delivered wirelessly during a routine clinic visit. For external devices, the manufacturer may provide updated software files or replacement units. Contact your healthcare provider to determine whether your specific device and software version are affected and what action is recommended.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency, Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.